OpenBilldrug price receipt

NADAC week of 2026-10-14

CEVIMELINE HCL 30 MG CAPSULE

For 30 capsules

Pharmacies pay

$21.87 filed

30 × $0.72894 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$34.22 filed

30 × $1.14067 per EA, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18


The spread

1.6× estimated

Medicare paid 1.6× what pharmacies pay.

Part D averages every strength and form sold under “Cevimeline HCl” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$30.15 estimated

$21.87 + $3.28 (15%) + $5.00 fee per fill = $30.15

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

CEVIMELINE HCL 30 MG CAPSULE is how the CMS NADAC file names this product. The FDA NDC Directory lists it as “cevimeline hydrochloride” and “cevimeline”, as its NDCs’ listings variously write the nonproprietary name.

FDA gives its dosage form as capsule and its route as oral.

FDA lists 9 labelers (the companies named on the label) for its NDCs, among them Hikma Pharmaceuticals USA Inc., Cosette Pharmaceuticals, Inc. and Rising Pharma Holdings, Inc.

FDA’s Established Pharmacologic Class for it is Cholinergic Receptor Agonist.

The NADAC file of 2026-10-14 prices it under 10 NDCs (National Drug Codes).

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $21.87 for 30 capsules (30 × $0.72894 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 6, the CMS Covered Outpatient Drug Product File S/I/N drug category was not applied when grouping drugs for the calculation.

The 9 labelers

LabelerNDCsPharmacies pay per unit
Advagen Pharma Ltd2$0.72894 per EA filed
Aurobindo Pharma Limited1$0.72894 per EA filed
Bionpharma Inc1$0.72894 per EA filed
Cosette Pharmaceuticals, Inc.1$0.72894 per EA filed
Hikma Pharmaceuticals USA Inc.1$0.72894 per EA filed
Macleods Pharmaceuticals Limited1$0.72894 per EA filed
Rising Pharma Holdings, Inc.1$0.72894 per EA filed
Sun Pharmaceutical Industries, Inc.1$0.72894 per EA filed
Viona Pharmaceuticals Inc1$0.72894 per EA filed
All 10 NDCs, with labeler and price
  • 00054-0334-25 · Hikma Pharmaceuticals USA Inc. · $0.72894 per EA · eff. 2026-09-23 filed
  • 00713-0937-01 · Cosette Pharmaceuticals, Inc. · $0.72894 per EA · eff. 2026-09-23 filed
  • 16571-0657-10 · Rising Pharma Holdings, Inc. · $0.72894 per EA · eff. 2026-09-23 filed
  • 33342-0216-11 · Macleods Pharmaceuticals Limited · $0.72894 per EA · eff. 2026-09-23 filed
  • 59651-0422-01 · Aurobindo Pharma Limited · $0.72894 per EA · eff. 2026-09-23 filed
  • 63304-0479-01 · Sun Pharmaceutical Industries, Inc. · $0.72894 per EA · eff. 2026-09-23 filed
  • 69452-0316-20 · Bionpharma Inc · $0.72894 per EA · eff. 2026-09-23 filed
  • 72578-0208-01 · Viona Pharmaceuticals Inc · $0.72894 per EA · eff. 2026-09-23 filed
  • 72888-0118-01 · Advagen Pharma Ltd · $0.72894 per EA · eff. 2026-09-23 filed
  • 72888-0118-30 · Advagen Pharma Ltd · $0.72894 per EA · eff. 2026-09-23 filed

Other strengths, forms and brands

1 other product in the NADAC file shares an FDA nonproprietary name with CEVIMELINE HCL 30 MG CAPSULE.

ProductPharmacies pay per unitMedicare per unit
CEVIMELINE HCL 30 MG CAPSULE this page
generic · capsule
$0.72894 per EA filed
eff. 2026-09-23
$1.14067 per EA filed
Part D 2024 average
EVOXAC 30 MG CAPSULE
brand · capsule
$8.59086 per EA filed
eff. 2026-07-01
$7.68761 per EA filed
Part D 2024 average

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-07-01, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

The middle of its 10 NDCs’ NADAC prices is $0.72894 per EA filed.

Of the 7 other products in FDA’s Cholinergic Receptor Agonist class priced per EA, 3 have a higher middle NADAC price and 4 a lower one. The one in the middle is PILOCARPINE HCL 7.5 MG TABLET, at $0.35404 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What Medicare paid

Medicare Part D paid $34.22 for 30 capsules, at an average of $1.14067 per EA in 2024 (2024-01-01 to 2024-12-31) for “Cevimeline HCl”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 113,139 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Questions

Why is the comparison with Medicare for CEVIMELINE HCL 30 MG CAPSULE labelled estimated?
Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Cevimeline HCl / Cevimeline HCl: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on generic name.